NASDAQ:ADVM   Adverum Biotechnologies, Inc
With the recent advancements about the possible change of board members and the earnings report, finally ADVM should start its climb. The first target is $3.80.
Comment: Decrease in the short volume ratio on the stock is also a positive sign. Despite a penny increment sell wall, we are expecting the climb to resume.
Comment: It is making its comeback. With the institutional support for the success of the company, my target price is $5.60 in the short to middle term. As soon as the issues with the Phase 2 incidence is discovered, the price will slowly regain its valued range of $15-$20.

Related Ideas